Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

BACKGROUND: This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, Taroh, Lee, Kyung Hee, Rha, Sun Young, Sasaki, Yasutsuna, Park, Se Hoon, Komatsu, Yoshito, Yasui, Hirofumi, Kim, Tae-You, Yamaguchi, Kensei, Fuse, Nozomu, Yamada, Yasuhide, Ura, Takashi, Kim, Si-Young, Munakata, Masaki, Saitoh, Soh, Nishio, Kazuto, Morita, Satoshi, Yamamoto, Eriko, Zhang, Qingwei, Kim, Jung-mi, Kim, Yeul Hong, Sakata, Yuh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572054/
https://www.ncbi.nlm.nih.gov/pubmed/25185971
http://dx.doi.org/10.1007/s10120-014-0420-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572054/
https://www.ncbi.nlm.nih.gov/pubmed/25185971
http://dx.doi.org/10.1007/s10120-014-0420-9

Ejemplares similares